Observational study in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Ivan S SamolygoDepartment of Propaedeutics of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation. ivan.samolygo.03@bk.ru.ORCID http://orcid.org/0000-0002-8307-5168
Mikhail P KostinovLaboratory of Vaccine Prevention and Immunotherapy of Allergic Diseases, Federal State Budgetary Scientific Institution «I. Mechnikov Research Institute of Vaccines and Sera», 5a Maly Kazenniy Lane, 105064, Moscow, Russian Federation. monolit.96@mail.ru.ORCID http://orcid.org/0000-0002-1382-9403
Marina A ManinaDepartment of Propaedeutics of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0003-2560-6722
Albina S PestovaDepartment of Propaedeutics of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0002-8355-3457
Anton S AntishinDepartment of Propaedeutics of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0002-5237-7817
Alexander V NovikovDepartment of Internal, Occupational Diseases and Rheumatology at the N.V. Sklifosovsky Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenovskiy University), 11/5 Rossolimo str, Moscow, 119435, Russian Federation.ORCID http://orcid.org/0000-0001-9572-4818
Pavel A StribulInstitute of Clinical Morphology and Digital Pathology, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 1/1 Abrikosovsky lane, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0001-5179-6940
Ekaterina A YablokovaDepartment of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0003-3364-610X
Alexey A TinkovLaboratory of Molecular Dietetics, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya str, Moscow, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0003-0348-6192
Svetlana I ErdesDepartment of Propaedeutics of Children's Diseases, Institute of Child's Health, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University (Sechenov University), 19 Bolshaya Pirogovskaya St., Bldg. 1, 119435, Moscow, Russian Federation.ORCID http://orcid.org/0000-0001-8689-7602
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Children with inflammatory bowel disease are at increased risk of infectious diseases, including vaccine-preventable infections, due to immune dysregulation and immunosuppressive therapy. Data on the persistence of protective antibodies against measles and rubella in this population remain limited. To evaluate the seroprotective levels of IgG antibodies to measles and rubella in children with IBD and identify factors associated with antibody loss. A prospective observational study included 93 pediatric patients with IBD. IgG antibodies against measles and rubella were measured using ELISA. Vaccination status, clinical activity indices (PUCAI, PCDAI), and immunosuppressive therapies were documented. Survival analysis using Cox regression assessed factors influencing antibody persistence. Seroprotection rates were 65.5% for measles and 76% for rubella. Complete vaccination was achieved by 68.2% and 72% of patients for measles and rubella, respectively. Patients with full vaccination had significantly higher antibody levels. Younger age (<6 years) was associated with an increased risk of antibody loss: for measles, HR 21.58 (95% CI 4.46 – 104.40, p < 0.001), and for rubella in univariate analysis, HR 6.44 (95% CI 1.47–28.19, p=0.013). Incomplete vaccination increased the risk of antibody loss for measles (HR 2.76; 95% CI 1.31 – 5.79; p=0.007) and rubella (HR 2.53; 95% CI 1.06 – 6.01; p=0.036) in univariate analyses, but lost significance after adjustment in multivariate models. Immunosuppressive therapy did not significantly affect antibody levels. The highest risk groups for antibody loss were identified as High risk for measles (70% loss) and Intermediate-High risk for rubella (50% loss). In children with IBD, completed vaccination does not always guarantee protective antibody levels. Younger age and incomplete vaccination are key predictors of antibody loss. These findings highlight the need for personalized vaccination strategies and regular serological monitoring in this vulnerable population.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Factors influencing post-vaccination antibody levels to measles and rubella in children with inflammatory bowel disease. · full record | OpenQuestion